Reading Hospital McGlinn Cancer Institute at Phoenixville — Phoenixville, Pennsylvania

Reading Hospital McGlinn Cancer Institute at Phoenixville is a clinical research site located in Phoenixville, Pennsylvania, United States 19460.

Crixeo Health Trust Score: 77/100 (FAIR). This profile has not yet been claimed by the site owner.

Reading Hospital McGlinn Cancer Institute at Phoenixville has participated in 20 clinical trials with 18 currently active.

Therapeutic areas: Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome.

Sponsors: National Cancer Institute (NCI), NRG Oncology, Alliance for Clinical Trials in Oncology.

Sponsor Feasibility Report

Trust Score: 77/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Reading Hospital McGlinn Cancer Institute at Phoenixville?

Reading Hospital McGlinn Cancer Institute at Phoenixville has a Crixeo Trust Score of 77/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Reading Hospital McGlinn Cancer Institute at Phoenixville conducted?

Reading Hospital McGlinn Cancer Institute at Phoenixville has 20 clinical trials on record, with 18 currently active. Their work covers Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome.

Is Reading Hospital McGlinn Cancer Institute at Phoenixville accredited by Crixeo Health?

Yes — Reading Hospital McGlinn Cancer Institute at Phoenixville holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Reading Hospital McGlinn Cancer Institute at Phoenixville?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.